文献速递艾滋病与性传播感染

抗逆转录病毒药物向母乳中的转移:瑞士母婴HIV队列研究的一项前瞻性研究

Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

瑞士母婴HIV队列前瞻性纳入21对母婴,定量检测母乳与母体血浆中抗逆转录病毒药物浓度。拉替拉韦、比克替拉韦、利匹韦林、达芦那韦/利托那韦、替诺福韦艾拉酚胺的乳汁/血浆比值各异,估算婴儿每日剂量均低,但部分药物暴露低于或高于有效浓度,作者认为需更多数据支持母乳喂养。

要点

  • 21对母婴纳入,含拉替拉韦10例、比克替拉韦1例等 newer ARVs。
  • 估算婴儿每日剂量均低,所有药物相对婴儿剂量暴露指数<10%。
  • 部分药物暴露低于或高于有效浓度,作者提出耐药担忧。

核心结论

  • 抗逆转录病毒药物向母乳转移程度不一,估算婴儿每日剂量低,但部分药物暴露低于或高于有效浓度,若发生HIV感染有耐药发展担忧,需更多数据支持母乳喂养。

研究设计与样本

  • 前瞻性研究,纳入21对希望母乳喂养的母婴,无论其抗逆转录病毒治疗方案。

主要发现

  • 未检测到HIV垂直传播(1名婴儿仍在母乳喂养)。
  • 乳汁/血浆比值中位数:拉替拉韦每日一次/两次为0.96/0.39,比克替拉韦0.01,利匹韦林1.08,达芦那韦/利托那韦0.12,替诺福韦艾拉酚胺4.09。
  • 估算婴儿每日剂量(mg/kg)中位数:拉替拉韦每日一次/两次为0.02/0.25,比克替拉韦0.01,利匹韦林0.02,达芦那韦/利托那韦0.05,替诺福韦艾拉酚胺0.007,所有药物相对婴儿剂量暴露指数<10%。

局限性

  • 作者认为需要更多关于这一潜在风险的数据以更好地支持母乳喂养。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In 2018, Switzerland changed its guidelines to support women living with HIV wishing to breastfeed. The exposure of antiretroviral drugs (ARVs) in breastmilk and the ingested daily dose by the breastfed infant are understudied, notably for newer ARVs. This study aimed to quantify ARV concentrations in maternal plasma and breastmilk to determine the milk/plasma ratio, to estimate daily infant ARV dose from breastfeeding and to measure ARV concentrations in infants. METHODS: All women wishing to breastfeed were included, regardless of their ARV treatment. Breastmilk and maternal plasma samples were mostly collected at mid-dosing interval. RESULTS: Twenty-one mother/child pairs were enrolled; of those several were on newer ARVs including 10 raltegravir, 1 bictegravir, 2 rilpivirine, 2 darunavir/ritonavir and 3 tenofovir alafenamide. No vertical HIV transmission was detected (one infant still breastfed). The median milk/plasma ratios were 0.96/0.39 for raltegravir once/twice daily, 0.01 for bictegravir, 1.08 for rilpivirine, 0.12 for darunavir/ritonavir and 4.09 for tenofovir alafenamide. The median estimated infant daily dose (mg/kg) from breastfeeding was 0.02/0.25 for raltegravir once/twice daily, 0.01 for bictegravir, 0.02 for rilpivirine, 0.05 for darunavir/ritonavir and 0.007 for tenofovir alafenamide, resulting in relative infant dose <10% exposure index for all ARVs. CONCLUSIONS: ARVs were transferred to a variable extent in breastmilk. Nevertheless, the estimated daily ARV dose from breastfeeding remained low. Differential ARV exposure was observed in breastfed infants with some ARVs being below/above their effective concentrations raising the concern of resistance development if HIV infection occurs. More data on this potential risk are warranted to better support breastfeeding.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Aebi-Popp K, Kahlert CR, Crisinel PA, et al. Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study. J Antimicrob Chemother. 2022. PMID: 36177836. doi:10.1093/jac/dkac337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。